ArticlePharmaceutics2022
Amphotericin B-PEG Conjugates of ZnO Nanoparticles: Enhancement Antifungal Activity with Minimal Toxicity.
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 34 citations in OpenAlex.
- Polyethylene glycol functionalization modulates the toxicity of zinc oxide quantum dots: a multilevel characterization and toxicological study of Channa punctatus Bloch.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Biosynthesized ZnO nanoparticles enhance salt tolerance in Brassica Napus through antioxidant and gene regulatory pathways.BMC plant biology · 2026Article
- Celastrol boosts fluconazole efficacy against vaginal candidiasis: in vitro and in vivo evidence.AMB Express · 2025Article
- Polyene-Based Derivatives with Antifungal Activities.Pharmaceutics · 2024Review
- The anti-staphylococcal fusidic acid as an efflux pump inhibitor combined with fluconazole against vaginal candidiasis in mouse model.BMC microbiology · 2024Article
- Inorganic Nanoparticles: Tools to Emphasize the Janus Face of Amphotericin B.Antibiotics (Basel, Switzerland) · 2023Review
- What's old is new again: Insights into diabetic foot microbiome.World journal of diabetes · 2023Review
- Diminishing the Pathogenesis of the Food-Borne PathogenBiology · 2023Article
- Approved Nanomedicine against Diseases.Pharmaceutics · 2023Review
- Metal Nanoparticles to CombatMicroorganisms · 2023Review
- Biofilm Lifestyle in Recurrent Urinary Tract Infections.Life (Basel, Switzerland) · 2023Review
- Polyol-mediated zinc oxide nanoparticles using the refluxing method as an efficient photocatalytic and antimicrobial agent.Frontiers in bioengineering and biotechnology · 2023Article
- Hiring of the Anti-Quorum Sensing Activities of Hypoglycemic Agent Linagliptin to Alleviate theMicroorganisms · 2022Article
- Nanoparticles for Antimicrobial Agents Delivery-An Up-to-Date Review.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amphotericin B (AMB) is commonly used to treat life-threatening systemic fungal infections. AMB formulations that are more efficient and less nephrotoxic are currently unmet needs. In the current study, new ZnO-PEGylated AMB (ZnO-AMB-PEG) nanoparticles (NPs) were synthesized and their antifungal effects on the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.